ONC vs the Top Picks average
| Pillar | ONC | Book avg | Diff |
|---|---|---|---|
| Quality | 0.61 | 0.84 | -0.23 |
| Growth | 0.97 | 0.87 | +0.10 |
| Value | 0.58 | 0.76 | -0.18 |
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
| 30-day change | +6.2% |
|---|---|
| 90-day change | +7.6% |
| Forward EPS estimate | $10.28 |
Over the last 90 days, what analysts expect ONC to earn is materially higher (+7.6%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
BeOne Medicines AG (ONC): score, valuation & FAQ
BeOne Medicines AG (ONC) is a Biotechnology company that scores 69.9 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and PEG (B+). On valuation, ONC sits about 19% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 9% annual free-cash-flow growth over the next decade.
Is ONC a good stock to buy?
Bull Rankings scores ONC 69.9 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A) and PEG (B+). A score is a quantitative screen of BeOne Medicines AG's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ONC score 69.9 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ONC earns its highest marks on Rev (A) and PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ONC overvalued or undervalued?
Based on $371.98, ONC sits about 19% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 9% annual free-cash-flow growth over the next decade. It trades at a 66.7x P/E (graded C). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ONC?
The bear case centers on the premium valuation: a PE of 66.7x is far above sector averages and assumes continued double‑digit growth, yet the Bull Rankings model flags a weak Value pillar (58) and signals diluting shareholders, which could erode earnings per share. A slowdown in BRUKINSA uptake or a missed regulatory milestone would validate the high multiple as over‑optimistic and trigger a price correction.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.